Key statistics
On Thursday, Shanghai Junshi Biosciences Co Ltd (1877:HKG) closed at 15.30, 66.85% above the 52 week low of 9.17 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.98 |
---|---|
High | 16.40 |
Low | 15.26 |
Bid | 15.30 |
Offer | 15.36 |
Previous close | 15.70 |
Average volume | 3.19m |
---|---|
Shares outstanding | 985.69m |
Free float | 150.34m |
P/E (TTM) | -- |
Market cap | 32.30bn HKD |
EPS (TTM) | -2.15 HKD |
Data delayed at least 15 minutes, as of Oct 10 2024 09:08 BST.
More ▼
Announcements
- Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
More ▼